# 2026年1月10日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 预防术后胰腺炎：超声内镜引导下胆总管十二指肠吻合术与内镜逆行胰胆管造影术治疗恶性远端胆道梗阻的随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41511419)
**期刊：** Gastroenterology
**PMID：** 41511419
**DOI：** 10.1053/j.gastro.2025.09.003

### 第一部分 原文与翻译

**英文原标题：** Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.

> **英文摘要：**
> BACKGROUND & AIMS: Postprocedural pancreatitis is the most common adverse event (AE) associated with endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) using a lumen-apposing metal stent is emerging as a promising approach for managing malignant distal biliary obstruction, offering the potential to lower the risk of postprocedural pancreatitis. METHODS: This was a multicenter randomized study, enrolling consecutive patients admitted for obstructive jaundice due to malignant distal biliary obstruction with dilated common bile duct (≥15 mm). Patients were randomly allocated to receive EUS-CDS or ERCP for primary biliary drainage. This was a superiority trial with postprocedural acute pancreatitis as primary outcome. Other outcomes included technical success, clinical success, AEs, 6-month stent patency rate, and overall survival. Analyses were performed according to intention-to-treat principles. RESULTS: Between April 2021 and October 2023, 220 patients were enrolled in the study (EUS-CDS, 111; ERCP, 109). EUS-CDS group showed a lower risk for postprocedural acute pancreatitis (1.8% in EUS-CDS vs 7.3% in ERCP; relative risk, 0.25; 95% confidence interval, 0.07-0.88). Technical success was achieved in 94.6% in EUS-CDS group vs 78.9% ERCP group (P < .001), in a mean procedural time of 13.5 ± 11.6 minutes and 24.7 ± 14.9 minutes, respectively (P <.001). No differences were found in other AEs (19.8% in EUS-CDS vs 21.1% in ERCP; relative risk, 0.94; 95% confidence interval, 0.56-1.58), clinical success, stent patency, or overall mortality. CONCLUSIONS: EUS-CDS is superior to ERCP in reducing postprocedural acute pancreatitis risk. However, the overall risk of AEs was not significantly different and warrants further investigation. Additionally EUS-CDS showed improved technical success and comparable clinical efficacy. These results support a potential role of EUS-CDS as primary approach in selected patients with dilated common bile duct (ClinicalTrials.gov, Number: NCT04099862).

> **中文摘要：**
> 背景与目的：术后胰腺炎是与内镜逆行胰胆管造影术（ERCP）相关的最常见不良事件（AE）。使用管腔对合金属支架的超声内镜引导下胆总管十二指肠吻合术（EUS-CDS）正成为治疗恶性远端胆道梗阻的一种有前景的方法，有望降低术后胰腺炎风险。方法：这是一项多中心随机研究，连续纳入因恶性远端胆道梗阻伴胆总管扩张（≥15 mm）导致梗阻性黄疸而入院的患者。患者被随机分配接受EUS-CDS或ERCP作为初始胆道引流。本研究是一项优效性试验，主要结局是术后急性胰腺炎。其他结局包括技术成功率、临床成功率、不良事件、6个月支架通畅率和总生存期。分析遵循意向性治疗原则。结果：2021年4月至2023年10月期间，共有220名患者入组（EUS-CDS组111人；ERCP组109人）。EUS-CDS组显示出较低的术后急性胰腺炎风险（EUS-CDS组1.8% vs ERCP组7.3%；相对风险，0.25；95%置信区间，0.07-0.88）。EUS-CDS组技术成功率为94.6%，ERCP组为78.9%（P < .001），平均手术时间分别为13.5 ± 11.6分钟和24.7 ± 14.9分钟（P <.001）。在其他不良事件（EUS-CDS组19.8% vs ERCP组21.1%；相对风险，0.94；95%置信区间，0.56-1.58）、临床成功率、支架通畅率或总死亡率方面未发现差异。结论：在降低术后急性胰腺炎风险方面，EUS-CDS优于ERCP。然而，总体不良事件风险无显著差异，值得进一步研究。此外，EUS-CDS显示出更高的技术成功率和相当的临床疗效。这些结果支持EUS-CDS作为胆总管扩张的特定患者中一种潜在的初始治疗选择（ClinicalTrials.gov，编号：NCT04099862）。

### 第二部分 AI 大师评价

本研究旨在比较EUS-CDS与ERCP作为恶性远端胆道梗阻初始引流手段时，预防术后胰腺炎的效果。研究设计为多中心随机优效性试验，主要终点明确。核心发现是EUS-CDS能显著降低术后胰腺炎风险，并具有更高的技术成功率和更短的手术时间，但两组总体不良事件发生率无差异。其创新性在于为特定患者（胆总管扩张≥15 mm）提供了一种可能更优的初始引流方案，但局限性在于总体安全性优势未显现，且结果可能仅适用于胆管显著扩张的特定人群，需进一步研究验证其广泛适用性。

---

## 2. TAPISTRY：一项在肿瘤突变负荷高（TMB-High）肿瘤患者中评估阿特珠单抗的II期研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41511400)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41511400
**DOI：** 10.1158/1078-0432.CCR-25-3336

### 第一部分 原文与翻译

**英文原标题：** TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

> **英文摘要：**
> PURPOSE: Patients with tumor mutational burden (TMB)-high tumors can derive benefit from atezolizumab, though previous studies have used inconsistent TMB cutoffs. We report data for atezolizumab in patients with TMB-high solid tumors from the phase II, TAPISTRY multicohort trial, using TMB cutoffs of ≥13 and ≥16 mutations/megabase (mut/Mb). METHODS: Patients with PD-L1 inhibitor-naïve,TMB-high (≥13 mut/Mb) advanced/metastatic solid tumors received atezolizumab every 21 days (1200 mg adults, 15 mg/kg [up to 1200 mg/kg] children). PRIMARY ENDPOINT: independent review committee (IRC)-assessed objective response rate (ORR) for TMB ≥16 mut/Mb. Secondary endpoints (using TMB ≥13 mut/Mb) included IRC-assessed ORR, duration of response (DOR), progression-free survival (PFS), and safety. RESULTS: As of November 9, 2023 (median survival follow-up: 9.8 months), 148 patients received treatment. Median age was 63 years, 31.8% of patients had >2 prior therapy lines, and the most common tumor types were colorectal (29.1%), breast (8.8%), and gastroesophageal (8.8%). IRC-assessed ORR was 22.3% (95% CI, 15.0-31.2) with TMB ≥16 mut/Mb (n=112), and 20.2% (95% CI, 13.6-28.1) with TMB ≥13 mut/Mb (n=129). Median IRC-assessed DOR was not estimable. Median IRC-assessed PFS was 2.8 (95% CI, 1.7-5.4) and 2.7 (95% CI, 1.5-4.2) months using TMB ≥16 and ≥13 mut/Mb, respectively. Adverse events (AEs) were reported in 93.2% of patients, of which 53.4% were treatment-related (no grade 5) and 40.5% were grade ≥3. CONCLUSION: Atezolizumab led to moderate antitumor activity in various TMB-high solid tumors. Safety was consistent with previous reports. CLINICAL TRIAL NUMBER: NCT04589845.

> **中文摘要：**
> 目的：肿瘤突变负荷（TMB）高的患者可以从阿特珠单抗治疗中获益，但既往研究使用的TMB界值不一致。我们报告了来自II期、多队列TAPISTRY试验中，使用≥13和≥16个突变/兆碱基（mut/Mb）作为TMB界值，阿特珠单抗在TMB高的实体瘤患者中的数据。方法：既往未接受过PD-L1抑制剂治疗、TMB高（≥13 mut/Mb）的晚期/转移性实体瘤患者每21天接受一次阿特珠单抗治疗（成人1200 mg，儿童15 mg/kg [最高1200 mg/kg]）。主要终点：独立评审委员会（IRC）评估的TMB ≥16 mut/Mb患者的客观缓解率（ORR）。次要终点（使用TMB ≥13 mut/Mb）包括IRC评估的ORR、缓解持续时间（DOR）、无进展生存期（PFS）和安全性。结果：截至2023年11月9日（中位生存随访时间：9.8个月），148例患者接受了治疗。中位年龄为63岁，31.8%的患者既往接受过>2线治疗，最常见的肿瘤类型为结直肠癌（29.1%）、乳腺癌（8.8%）和胃食管癌（8.8%）。IRC评估的ORR在TMB ≥16 mut/Mb组（n=112）为22.3%（95% CI，15.0-31.2），在TMB ≥13 mut/Mb组（n=129）为20.2%（95% CI，13.6-28.1）。IRC评估的中位DOR无法估计。使用TMB ≥16和≥13 mut/Mb界值时，IRC评估的中位PFS分别为2.8个月（95% CI，1.7-5.4）和2.7个月（95% CI，1.5-4.2）。93.2%的患者报告了不良事件（AEs），其中53.4%与治疗相关（无5级事件），40.5%为≥3级。结论：阿特珠单抗在多种TMB高的实体瘤中显示出中等的抗肿瘤活性。安全性与既往报告一致。临床试验编号：NCT04589845。

### 第二部分 AI 大师评价

本研究旨在通过II期TAPISTRY试验，评估阿特珠单抗在TMB-High实体瘤患者中的疗效与安全性，并明确两个常用TMB界值（≥13和≥16 mut/Mb）下的临床结局。研究设计严谨，采用IRC评估主要终点，纳入了经多线治疗的患者群体，具有较好的临床代表性。核心发现是阿特珠单抗在此类患者中显示出中等且一致的客观缓解率（约20-22%），但中位PFS较短（约2.7-2.8个月），且≥3级治疗相关不良事件发生率较高（40.5%）。其创新性在于直接对比了不同TMB界值下的疗效数据，为临床实践中TMB作为生物标志物的应用提供了更精细的参考；局限性在于研究为单臂设计，缺乏与标准治疗或安慰剂的直接对照，且中位DOR无法估计，长期疗效数据尚不明确。

---

## 3. 短程与长程放疗在局部晚期直肠癌中的差异性免疫效应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41511399)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41511399
**DOI：** 10.1158/1078-0432.CCR-25-2733

### 第一部分 原文与翻译

**英文原标题：** Differential Immunological Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer.

> **英文摘要：**
> PURPOSE: Two dominant neoadjuvant radiotherapy (RT) regimens are in common use for locally advanced rectal cancer (LARC): long-course radiotherapy (LCRT;25x1.8Gy) with concomitant chemotherapy and short-course radiotherapy (SCRT;5x5Gy) typically followed by systemic chemotherapy. This study uses serial sampling to investigate the evolution of systemic and local immune responses to different radiotherapy regimens in LARC.
> 
> EXPERIMENTAL DESIGN: We conducted a serial sampling study involving patients receiving radiotherapy for LARC, in which longitudinal blood and tumor biospecimens were collected at baseline, and at 2, 6, and 12 weeks after treatment initiation. Leukocyte concentrations via full blood count and a multiplex cytokine ELISA of plasma samples measured systemic changes. Multiplex immunofluorescence (CD8 and FOXP3) and RNA-sequencing of tumor biopsies were used to assess local changes.
> 
> RESULTS: Circulating lymphocyte concentrations tended to increase in SCRT patients and decrease in LCRT patients between week 2 and week 6 and were significantly lower in LCRT patients compared to SCRT patients at week 6 (p<0.0001) and week 12 (p=0.019). Additionally, we report higher densities of CD8+ and FOXP3+ tumoral lymphocytes from SCRT patients compared to LCRT patients at week 2 (CD8 p=0.053, FOXP3 p=0.023) and week 6 (CD8 p=0.035, FOXP3 p=0.0016).
> 
> CONCLUSIONS: SCRT is less lympho-depleting and induces more frequent increases in intra-tumoral T cell infiltration compared to LCRT. These results are relevant to the field of radiation-immune-oncology combination studies in LARC. Furthermore, these findings may underpin early trial results, where higher rates of response to radiotherapy-immune checkpoint inhibitor combinations have been reported with SCRT-based regimens.

> **中文摘要：**
> 目的：局部晚期直肠癌（LARC）常用的两种主要新辅助放疗方案为：长程放疗（LCRT；25x1.8Gy）联合化疗，以及短程放疗（SCRT；5x5Gy）后通常进行全身化疗。本研究采用系列采样方法，旨在探究LARC患者对不同放疗方案产生的全身及局部免疫反应的演变过程。
> 
> 实验设计：我们开展了一项针对接受放疗的LARC患者的系列采样研究，在基线以及治疗开始后第2、6、12周纵向采集血液和肿瘤生物样本。通过全血细胞计数检测白细胞浓度，并使用多重细胞因子ELISA检测血浆样本，以评估全身性变化。采用多重免疫荧光（CD8和FOXP3）和肿瘤活检组织的RNA测序来评估局部变化。
> 
> 结果：在第2周至第6周期间，SCRT患者的循环淋巴细胞浓度呈上升趋势，而LCRT患者则呈下降趋势；并且，在第6周（p<0.0001）和第12周（p=0.019），LCRT患者的循环淋巴细胞浓度显著低于SCRT患者。此外，我们报告在第2周（CD8 p=0.053，FOXP3 p=0.023）和第6周（CD8 p=0.035，FOXP3 p=0.0016），SCRT患者肿瘤内CD8+和FOXP3+淋巴细胞的密度均高于LCRT患者。
> 
> 结论：与LCRT相比，SCRT对淋巴细胞的耗竭作用更小，并能更频繁地诱导肿瘤内T细胞浸润的增加。这些结果与LARC领域的放疗-免疫肿瘤学联合研究相关。此外，这些发现可能为早期临床试验结果提供依据，已有报道显示基于SCRT的方案对放疗-免疫检查点抑制剂联合治疗具有更高的应答率。

### 第二部分 AI 大师评价

本研究通过系列采样设计，系统比较了局部晚期直肠癌两种主流新辅助放疗方案（短程与长程）对全身及局部免疫微环境的动态影响。核心发现是短程放疗相较于长程放疗，对循环淋巴细胞的耗竭更少，并能更有效地诱导肿瘤内CD8+和FOXP3+T细胞的浸润增加。这一发现为解释为何基于短程放疗的联合免疫治疗可能获得更高应答率提供了关键的免疫学机制依据，具有明确的临床转化价值。研究的局限性在于样本量未知，且主要聚焦于免疫细胞数量和表型，对功能状态及长期临床结局的关联需进一步探索。

---

## 4. Sym024与CD73同源二聚体上的独特表位相互作用，促进有效的双价结合以改善抗PD1疗法。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41511395)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41511395
**DOI：** 10.1158/1078-0432.CCR-25-2406

### 第一部分 原文与翻译

**英文原标题：** Sym024 interacts with a unique epitope on the CD73 homodimer, favoring effective bivalent binding to improve anti-PD1 therapy.

> **英文摘要：**
> PURPOSE: Adenosine signaling may be a central immune suppressive mechanism in several cancers, and blockade of the rate-limiting CD73 AMP-to-adenosine enzyme has been demonstrated to improve clinical efficacy of PD(L)-1 immune therapy. However, deep inhibition of CD73 activity could prove difficult in tumor environments with a constant AMP supply and high CD73 levels. Here, we sought to identify, characterize, and benchmark a novel antagonistic anti-CD73 antibody, Sym024 (S95024), and to structurally decode its mode of action. EXPERIMENTAL DESIGN: Sym024, selected via functional antibody repertoire screening, was tested against benchmark anti-CD73 antibodies in primary细胞、细胞系体外结合、CD73酶活性和T细胞活化实验中。其在体内的肿瘤生长抑制作用在具有免疫活性或免疫缺陷小鼠的移植人源或鼠源肿瘤中进行了检测，并评估了瘤内酶活性抑制和免疫细胞募集情况。我们利用表面等离子共振、冷冻电镜、定点诱变以及通过尺寸排阻色谱结合光散射质量检测进行群体水平复合物形成分析，研究了Sym024-CD73相互作用。在猴子中评估了临床前安全性和药代动力学。 RESULTS: Sym024在广泛的酶表达水平范围内均能有效阻断CD73，相较于基准抗CD73抗体表现更优；它在体外和体内均增强了PD-1阻断的疗效。我们的结构数据表明，一种独特的一对一Sym024-CD73相互作用导致了这种全面的抑制。未观察到临床前安全性警示，且Sym024的药代动力学特征支持标准的临床给药方案。 CONCLUSIONS: Sym024表现出的全面CD73抑制可能提高抗PD(L)-1/抗CD73联合治疗的疗效。

> **中文摘要：**
> 目的：腺苷信号通路可能是多种癌症的核心免疫抑制机制，阻断限速酶CD73（AMP转化为腺苷）已被证明可提高PD(L)-1免疫疗法的临床疗效。然而，在持续供应AMP和高CD73水平的肿瘤微环境中，深度抑制CD73活性可能很困难。本研究旨在鉴定、表征并评估一种新型拮抗性抗CD73抗体Sym024 (S95024)，并从结构上解析其作用模式。实验设计：通过功能性抗体库筛选获得的Sym024，在原代细胞、细胞系体外结合、CD73酶活性及T细胞活化实验中，与基准抗CD73抗体进行了对比测试。其在体内的肿瘤生长抑制作用在具有免疫活性或免疫缺陷小鼠的移植人源或鼠源肿瘤模型中进行了检验，并评估了瘤内酶活性抑制和免疫细胞募集情况。我们利用表面等离子共振、冷冻电镜、定点诱变以及通过尺寸排阻色谱结合光散射质量检测进行群体水平复合物形成分析，研究了Sym024与CD73的相互作用。在猴子中评估了临床前安全性和药代动力学。结果：Sym024在广泛的酶表达水平范围内均能有效阻断CD73，相较于基准抗CD73抗体表现更优；它在体外和体内均增强了PD-1阻断的疗效。我们的结构数据表明，一种独特的一对一Sym024-CD73相互作用导致了这种全面的抑制。未观察到临床前安全性警示，且Sym024的药代动力学特征支持标准的临床给药方案。结论：Sym024表现出的全面CD73抑制可能提高抗PD(L)-1/抗CD73联合治疗的疗效。

### 第二部分 AI 大师评价

本研究旨在开发一种新型抗CD73抗体Sym024，以克服肿瘤微环境中深度抑制CD73的挑战。研究采用功能筛选、多维度体外/体内药效评估及结构生物学方法，系统揭示了Sym024通过靶向CD73同源二聚体独特表位实现一对一、双价结合，从而产生全面且强效的酶活性抑制。其核心创新在于从结构层面阐明了作用机制，并证实了其增强抗PD-1疗效的潜力及良好的临床前安全性，为联合免疫治疗提供了新策略。然而，研究结论主要基于临床前模型，其在复杂人体肿瘤微环境中的实际疗效与安全性仍需临床试验验证。

---

## 5. RESTORE随机对照试验：多学科康复计划对食管胃癌幸存者心肺功能的影响：勘误。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508347)
**期刊：** Annals of surgery
**PMID：** 41508347
**DOI：** 10.1097/SLA.0000000000006917

### 第一部分 原文与翻译

**英文原标题：** The RESTORE Randomized Controlled Trial: Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric Cancer Survivorship: Erratum.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究是一项针对食管胃癌幸存者的随机对照试验，旨在评估多学科康复计划对改善其心肺功能的影响。其核心在于探索非药物性干预在癌症长期生存管理中的价值。然而，由于输入信息仅为勘误通知且无摘要，无法评估其具体的研究方法、主要发现或结论。因此，该文献的创新性与局限性均无法基于现有信息进行判断，读者需查阅原始完整文献以获取详细信息。

---

## 6. 肝细胞癌肝移植扩大标准的网络荟萃分析与验证研究：甲胎蛋白的重要作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508341)
**期刊：** Clinical and molecular hepatology
**PMID：** 41508341
**DOI：** 10.3350/cmh.2025.0986

### 第一部分 原文与翻译

**英文原标题：** Network meta-analysis and validation study of expanded liver transplantation criteria for HCC: Significant role of AFP.

> **英文摘要：**
> BACKGROUND AND AIMS: Various expanded criteria (EC) for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) have been proposed to avoid the narrow nature of the Milan criteria (MC). To investigate which EC predicts more favorable outcomes in terms of overall survival (OS) and recurrence-free survival (RFS), we conducted a network meta-analysis (NMA). METHODS: A database search was conducted on PubMed, Embase, and the Cochrane Library, to identify studies comparing OS and RFS between patients within the MC and those exceeding the MC but within the EC. Effect sizes were assessed using hazard ratios (HR), which were pooled in a random-effects NMA. The NMA results were validated in an in-house cohort of 1,008 LT recipients. RESULTS: Of 22,466 articles identified, 35 studies contained 45 pairwise comparisons and were included in the NMA along with 8 different EC. The use of UCSF (HR, 1.43; 95% CI, 1.19-1.71), Up-to-Seven (HR, 1.50; 95% CI, 1.15-1.97), and Hangzhou criteria (HR, 1.69; 95% CI, 1.11-2.57) yielded OS results inferior to the MC. The MC had the highest rank probability of being best followed by Metroticket 2.0 model and Asan criteria in terms of OS and RFS, respectively. Both Metroticket 2.0 and AFP model yielded more favorable HCC-specific mortality than other EC in the validation cohort. CONCLUSION: Several EC, of which those of Metroticket 2.0 model were the best, yielded comparable outcomes to the MC. AFP-based EC such as Metroticket 2.0 and AFP model appeared to be useful in both the NMA and the validation cohort, suggesting a potential role in identifying selected low-risk patients beyond the MC.

> **中文摘要：**
> 背景与目的：为规避米兰标准（MC）的局限性，针对肝细胞癌（HCC）患者的肝移植（LT）已提出多种扩大标准（EC）。为探究哪种EC在总生存期（OS）和无复发生存期（RFS）方面能预测更佳结局，我们进行了一项网络荟萃分析（NMA）。方法：在PubMed、Embase和Cochrane Library数据库中进行检索，以识别比较符合MC的患者与超出MC但符合EC的患者在OS和RFS方面的研究。使用风险比（HR）评估效应量，并在随机效应NMA中进行合并。NMA结果在一个包含1,008名LT受者的内部队列中进行了验证。结果：在检索到的22,466篇文章中，35项研究包含45对比较，连同8种不同的EC被纳入NMA。使用UCSF标准（HR， 1.43； 95% CI， 1.19-1.71）、Up-to-Seven标准（HR， 1.50； 95% CI， 1.15-1.97）和杭州标准（HR， 1.69； 95% CI， 1.11-2.57）得出的OS结果均劣于MC。在OS和RFS方面，MC具有最高的最佳排序概率，其次是Metroticket 2.0模型和Asan标准。在验证队列中，Metroticket 2.0模型和AFP模型均比其他EC产生了更有利的HCC特异性死亡率。结论：几种EC（其中Metroticket 2.0模型最佳）取得了与MC相当的结局。基于甲胎蛋白（AFP）的EC（如Metroticket 2.0和AFP模型）在NMA和验证队列中均显示出实用性，表明其在筛选超出MC的低风险患者方面具有潜在作用。

### 第二部分 AI 大师评价

本研究旨在通过网络荟萃分析与内部队列验证，系统评估不同肝移植扩大标准对肝细胞癌患者预后的预测价值。其核心创新在于整合了多种标准进行间接比较，并首次在独立队列中验证了网络荟萃分析的结果，增强了结论的稳健性。研究发现，基于甲胎蛋白的Metroticket 2.0模型表现最佳，为超出米兰标准的患者提供了有效的风险分层工具，具有重要的临床指导意义。局限性在于纳入研究的异质性可能影响比较的精确性，且验证队列为单中心数据，未来需要多中心前瞻性研究进一步证实。

---

## 7. 肝细胞癌监测：一项卫生经济学评价

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508340)
**期刊：** Clinical and molecular hepatology
**PMID：** 41508340
**DOI：** 10.3350/cmh.2025.1060

### 第一部分 原文与翻译

**英文原标题：** Hepatocellular Carcinoma Surveillance: A Health Economic Evaluation.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) imposes a major health and economic burden worldwide, with disproportionate effects in low- and middle-income countries (LMICs). Surveillance in high-risk populations, typically using semiannual ultrasound and alpha-fetoprotein (AFP) testing, has been shown to be cost-effective by enabling earlier detection and improving survival. Yet, its overall value is reduced by poor adherence and the limited sensitivity of ultrasound, particularly in patients with metabolic-associated steatotic liver disease. Emerging approaches-including abbreviated MRI, multi-biomarker models (e.g., GALAD), and liquid biopsy assays such as methylated DNA markers-demonstrate greater diagnostic accuracy and potential economic advantages compared with conventional methods. Integration of artificial intelligence (AI) into imaging may further enhance efficiency and reduce downstream costs. Moving toward precision surveillance, guided by individualized risk stratification that incorporates etiology, fibrosis stage, and molecular profiles, can optimize allocation of resources and maximize cost-effectiveness at the population level. Interventions to improve adherence, including mailed outreach and behavioral economic incentives, have shown both clinical benefit and cost savings, underscoring the role of implementation science. Because socioeconomic disparities influence both access and outcomes, economic models must explicitly address equity to achieve sustainable impact. Future research should prioritize prospective trials that evaluate not only clinical performance but also the real-world cost-effectiveness of novel technologies and stratified surveillance strategies. For LMICs, adapting proven models into affordable, context-appropriate programs is essential. By combining prevention, precision risk assessment, innovative technologies, and equitable implementation, HCC surveillance can deliver both clinical and economic value, reducing the global burden of disease.

> **中文摘要：**
> 肝细胞癌（HCC）在全球范围内造成了重大的健康和经济负担，对低收入和中等收入国家（LMICs）的影响尤为严重。在高危人群中进行的监测（通常采用每半年一次的超声和甲胎蛋白（AFP）检测）已被证明具有成本效益，因为它能够实现早期检测并提高生存率。然而，其总体价值因依从性差以及超声敏感性有限（尤其是在代谢相关脂肪性肝病患者中）而降低。新兴方法——包括简化MRI、多生物标志物模型（例如GALAD）以及液体活检检测（如甲基化DNA标志物）——与传统方法相比，显示出更高的诊断准确性和潜在的经济优势。将人工智能（AI）整合到影像学中可能进一步提高效率并降低后续成本。迈向精准监测，以结合病因、纤维化分期和分子特征的个体化风险分层为指导，可以优化资源配置，并在人群层面最大化成本效益。提高依从性的干预措施，包括邮件外展和行为经济激励，已显示出临床获益和成本节约，这凸显了实施科学的作用。由于社会经济差异影响着可及性和结局，经济模型必须明确解决公平性问题，以实现可持续的影响。未来的研究应优先考虑前瞻性试验，这些试验不仅要评估临床性能，还要评估新技术和分层监测策略在真实世界中的成本效益。对于低收入和中等收入国家，将已验证的模式调整为负担得起且适合当地情况的方案至关重要。通过结合预防、精准风险评估、创新技术和公平实施，HCC监测可以同时提供临床和经济价值，减轻全球疾病负担。

### 第二部分 AI 大师评价

本文旨在从卫生经济学角度系统评估肝细胞癌（HCC）监测策略。文章核心在于指出传统超声联合AFP监测虽具成本效益，但受限于依从性与敏感性，并系统评述了简化MRI、液体活检、AI影像及精准风险分层等新兴技术/策略在提升诊断效能与经济性方面的潜力。其创新性在于将经济学评价与前沿技术、精准医学及实施科学（如提高依从性的干预）相结合，并强调了公平性在模型构建中的关键作用。局限性在于所讨论的多数新兴技术仍需前瞻性研究验证其真实世界的成本效益，尤其是在资源有限地区的适用性方案尚待探索。

---

## 8. 乙型肝炎病毒感染者合并丙型肝炎病毒或代谢功能障碍相关脂肪性肝病的治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508339)
**期刊：** Clinical and molecular hepatology
**PMID：** 41508339
**DOI：** 10.3350/cmh.2025.1227

### 第一部分 原文与翻译

**英文原标题：** Treatment Strategies for Patients with HBV Infection Coexisting with HCV or MASLD.

> **英文摘要：**
> Hepatitis B virus (HBV) remains a major cause of chronic liver diseases, especially in the Asia-Pacific region. In recent decades, coinfection with hepatitis C virus (HCV) and coexistence with metabolic dysfunction-associated steatotic liver disease (MASLD) have emerged as significant clinical concerns among HBV-infected subjects. Although global HBV vaccination programs and curative therapies for HCV have led to a marked decline in HBV/HCV coinfection, MASLD is rapidly becoming the predominant comorbidity due to the global surge in metabolic risk factors. HBV/HCV coinfection typically results in more severe liver damage, with unique challenges in antiviral treatment and risk of HBV reactivation post-HCV clearance. In contrast, HBV/MASLD overlap demonstrates complex metabolic-viral interactions that may influence viral replication, hepatitis B surface antigen seroclearance, fibrosis progression, and risk of hepatocellular carcinoma. This review critically compares the epidemiology, clinical outcomes, and management strategies of HBV patients with concurrent HCV or MASLD, while addressing current research gaps and proposing directions for future investigations.

> **中文摘要：**
> 乙型肝炎病毒（HBV）仍然是慢性肝病的主要原因，尤其是在亚太地区。近几十年来，HBV感染者合并丙型肝炎病毒（HCV）感染或与代谢功能障碍相关脂肪性肝病（MASLD）共存已成为重要的临床问题。尽管全球HBV疫苗接种计划和HCV的根治性疗法已导致HBV/HCV合并感染显著减少，但由于全球代谢危险因素的激增，MASLD正迅速成为主要的合并症。HBV/HCV合并感染通常导致更严重的肝损伤，在抗病毒治疗和HCV清除后HBV再激活风险方面存在独特挑战。相比之下，HBV/MASLD重叠则表现出复杂的代谢-病毒相互作用，可能影响病毒复制、乙型肝炎表面抗原血清清除、纤维化进展以及肝细胞癌风险。本综述批判性地比较了合并HCV或MASLD的HBV患者的流行病学、临床结局和管理策略，同时指出了当前的研究空白并提出了未来的研究方向。

### 第二部分 AI 大师评价

本综述旨在系统梳理并比较HBV感染者合并HCV感染或MASLD这两种不同临床场景的流行病学、临床特征及管理策略。其方法是对现有文献进行批判性回顾与比较分析，而非原始研究。核心发现指出，HBV/HCV合并感染虽因有效干预而减少，但肝损伤更重且治疗复杂；而HBV/MASLD重叠则因代谢因素流行而日益普遍，两者在病毒学、疾病进展及致癌风险上存在显著差异。其创新性在于聚焦于这两种日益重要的共病模式，并整合了最新的MASLD命名与概念，但作为综述，其结论受限于现有证据的质量与完整性，且对具体治疗方案的推荐深度有待未来前瞻性研究验证。

---

## 9. 阿司匹林用于预防代谢功能障碍相关脂肪性肝病患者的肝细胞癌：我们准备推进到何种程度？——关于“阿司匹林与MASLD患者HCC风险：一项结合遗传风险分析的全国性队列研究”的述评

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508334)
**期刊：** Clinical and molecular hepatology
**PMID：** 41508334
**DOI：** 10.3350/cmh.2025.1482

### 第一部分 原文与翻译

**英文原标题：** Aspirin for Hepatocellular Carcinoma Prevention in MASLD: How Far Are We Ready to Proceed? : Editorial on "Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇针对一项全国性队列研究的述评，核心目的是探讨阿司匹林在预防代谢功能障碍相关脂肪性肝病患者肝细胞癌方面的应用前景与证据强度。述评基于一项结合遗传风险分析的大型队列研究结果，旨在评估阿司匹林预防效果的真实世界证据。其创新性在于将药物预防策略置于特定肝病（MASLD）背景下，并整合遗传风险因素进行综合分析。然而，作为述评文章，其局限性在于本身不提供原始数据，主要依赖引述研究的发现进行观点阐述，结论的最终确立仍需等待更多前瞻性干预研究的验证。

---

## 10. CAR-T治疗失败后大B细胞淋巴瘤患者CAR后预后指数的多中心真实世界评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508112)
**期刊：** Journal of hematology & oncology
**PMID：** 41508112
**DOI：** 10.1186/s13045-025-01771-6

### 第一部分 原文与翻译

**英文原标题：** Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure.

> **英文摘要：**
> Most patients with large B-cell lymphoma (LBCL) progressing after CAR-T therapy experience poor survival and lack standardized treatment strategies. Prognostic tools are needed to guide decision-making at relapse. The Post-CAR Prognostic Index (PC-PI), recently proposed by Iacoboni et al., combines five routine clinical variables to stratify outcomes after CAR-T failure: ECOG (> 0), hemoglobin (< 10 g/dL), LDH (≥ 2xULN), number of extranodal sites (> 1) and time from CAR-T to progression (< 4 months). We evaluated the PC-PI in a retrospective multicenter study including 125 LBCL patients relapsing or refractory after axicabtagene-ciloleucel or tisagenlecleucel, treated between 2019 and 2023 across 16 Italian centers belonging to the Fondazione Italiana Linfomi network. Median overall survival (OS) was 4.9 months, with 6- and 12-month OS rates of 44.9% and 28.5%, respectively. The PC-PI discriminated prognosis effectively: high-risk patients had a median OS of 1.8 months, intermediate-high 2.2, intermediate-low 8.7, while in the low-risk group median OS was not reached (p<0.0001). Results remained consistent after excluding patients receiving only palliative care. Post-progression therapy markedly influenced survival: patients receiving active treatment achieved a median OS of 7.3 months versus 0.7 without further therapy (p<0.0001). Bispecific antibodies conferred the best outcomes (HR 0.44, p=0.02), with 6- and 12-month OS rates of 90% and 55%. Our findings confirm the prognostic value of the PC-PI and support its use in clinical practice as a tool for risk-adapted management of LBCL after CAR-T failure.

> **中文摘要：**
> 大多数在CAR-T治疗后进展的大B细胞淋巴瘤（LBCL）患者生存期较差，且缺乏标准化的治疗策略。需要预后工具来指导复发时的决策。Iacoboni等人最近提出的CAR后预后指数（PC-PI）结合了五个常规临床变量，用于对CAR-T失败后的结局进行分层：ECOG（> 0）、血红蛋白（< 10 g/dL）、LDH（≥ 2倍正常值上限）、结外病灶数量（> 1）以及从CAR-T到进展的时间（< 4个月）。我们在一项回顾性多中心研究中评估了PC-PI，该研究纳入了125例在axicabtagene-ciloleucel或tisagenlecleucel治疗后复发或难治的LBCL患者，这些患者在2019年至2023年间于意大利淋巴瘤基金会网络内的16个意大利中心接受治疗。中位总生存期（OS）为4.9个月，6个月和12个月OS率分别为44.9%和28.5%。PC-PI能有效区分预后：高危患者的中位OS为1.8个月，中高危为2.2个月，中低危为8.7个月，而低危组的中位OS尚未达到（p<0.0001）。在排除仅接受姑息治疗的患者后，结果保持一致。进展后治疗显著影响生存：接受积极治疗的患者中位OS为7.3个月，而未接受进一步治疗的患者为0.7个月（p<0.0001）。双特异性抗体带来了最佳结局（HR 0.44， p=0.02），其6个月和12个月OS率分别为90%和55%。我们的研究结果证实了PC-PI的预后价值，并支持其作为CAR-T失败后LBCL风险适应性管理的工具在临床实践中使用。

### 第二部分 AI 大师评价

本研究旨在通过多中心真实世界数据，验证新近提出的CAR后预后指数（PC-PI）在CAR-T治疗失败后大B细胞淋巴瘤（LBCL）患者中的预后分层价值。研究回顾性分析了125例患者，证实PC-PI能有效区分出从低危到高危的不同生存结局组，并强调了进展后积极治疗（尤其是双特异性抗体）对生存的显著影响。其创新性在于首次在真实世界队列中独立验证了PC-PI这一简单、基于常规临床指标的预后工具，为临床决策提供了实用依据。局限性在于其回顾性设计，且患者后续治疗方案存在异质性，可能影响预后评估的精确性。

---

## 11. 阿替利珠单抗联合贝伐珠单抗和非铂类化疗治疗复发性卵巢癌：来自安慰剂对照AGO-OVAR 2.29/ENGOT-ov34 III期试验的最终结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41337696)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41337696
**DOI：** 10.1200/JCO-25-01210

### 第一部分 原文与翻译

**英文原标题：** Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

> **英文摘要：**
> PURPOSE: To evaluate atezolizumab combined with bevacizumab and non-platinum-based chemotherapy for recurrent ovarian cancer. METHODS: The double-blind randomized phase III AGO-OVAR 2.29/ENGOT-ov34 trial (ClinicalTrials.gov identifier: NCT03353831) enrolled patients with first or second relapse of ovarian cancer ≤6 months after completing platinum-based chemotherapy (or third relapse regardless of treatment-free interval). PD-L1 status was tested centrally (VENTANA SP142 assay) in recent (<3 months) biopsies before random assignment. All patients received bevacizumab and investigator-selected chemotherapy (once weekly paclitaxel or pegylated liposomal doxorubicin) until disease progression or toxicity, plus either atezolizumab 840 mg or placebo once every 2 weeks until progression (maximum 2 years), randomly assigned 1:1, and stratified by number of previous lines, planned chemotherapy, previous bevacizumab, and PD-L1 status. Primary end points were overall survival (OS) and progression-free survival (PFS) in the intention-to-treat population. RESULTS: Among 574 patients randomly assigned between September 2018 and July 2022, 72% were bevacizumab-pretreated, 36% had received three previous treatment lines, 26% had PD-L1-positive tumors, and 54% received paclitaxel with study therapy. After 418 patients had died, the hazard ratio for OS was 0.83 (95% CI, 0.68 to 1.01;  = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) and the hazard ratio for PFS was 0.87 (95% CI, 0.73 to 1.04;  = .12; median 6.4  6.7 months, respectively). OS hazard ratios were similar regardless of PD-L1 status. Grade ≥3 adverse events occurred in 72% of atezolizumab-treated and 69% of placebo patients. CONCLUSION: Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

> **中文摘要：**
> 目的：评估阿替利珠单抗联合贝伐珠单抗和非铂类化疗治疗复发性卵巢癌的疗效。方法：双盲随机III期试验AGO-OVAR 2.29/ENGOT-ov34（ClinicalTrials.gov标识符：NCT03353831）纳入了完成铂类化疗后≤6个月内首次或第二次复发的卵巢癌患者（或无论无治疗间期如何的第三次复发）。在随机分组前，对近期（<3个月）的活检标本进行了PD-L1状态中心检测（VENTANA SP142检测法）。所有患者均接受贝伐珠单抗和研究医生选择的化疗（每周一次紫杉醇或聚乙二醇化脂质体阿霉素）直至疾病进展或出现毒性，此外每2周一次接受阿替利珠单抗840 mg或安慰剂直至进展（最长2年）。患者按1:1随机分配，并根据既往治疗线数、计划化疗方案、既往是否使用过贝伐珠单抗以及PD-L1状态进行分层。主要终点是意向治疗人群的总生存期和无进展生存期。结果：在2018年9月至2022年7月期间随机分配的574例患者中，72%既往接受过贝伐珠单抗治疗，36%既往接受过三线治疗，26%为PD-L1阳性肿瘤，54%在研究治疗中接受了紫杉醇。在418例患者死亡后，总生存期的风险比为0.83（95% CI，0.68至1.01；P = .06；阿替利珠单抗组中位OS为14.2个月，安慰剂组为13.0个月），无进展生存期的风险比为0.87（95% CI，0.73至1.04；P = .12；中位PFS分别为6.4个月和6.7个月）。无论PD-L1状态如何，总生存期的风险比均相似。≥3级不良事件发生在72%的阿替利珠单抗治疗患者和69%的安慰剂组患者中。结论：对于不适合铂类治疗的复发性卵巢癌患者，阿替利珠单抗联合贝伐珠单抗和化疗并未显著改善总生存期或无进展生存期。安全性特征与既往使用这些药物的经验一致。

### 第二部分 AI 大师评价

本研究是一项针对铂类不适用复发性卵巢癌的大型III期随机对照试验，旨在探索阿替利珠单抗（PD-L1抑制剂）联合贝伐珠单抗（抗血管生成药物）及非铂类化疗的疗效。其创新性在于将免疫治疗整合到这一难治人群的标准抗血管生成联合化疗方案中，并前瞻性地纳入了大量既往接受过贝伐珠单抗治疗的患者。最终结果表明，该三联方案未能显著改善总生存期或无进展生存期，且疗效与肿瘤PD-L1表达状态无关，这提示在当前治疗背景下，单纯添加PD-L1抑制剂可能不足以克服该人群的免疫抑制微环境。研究的局限性在于，尽管是阴性结果，但它为未来精准筛选免疫治疗获益人群及探索新的联合策略提供了关键数据。

---

## 12. 替沙仑基奥仑赛治疗复发/难治性大B细胞淋巴瘤的JULIET试验五年分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41252666)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41252666
**DOI：** 10.1200/JCO-25-00507

### 第一部分 原文与翻译

**英文原标题：** Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

> **英文摘要：**
> We report the 5-year analysis of tisagenlecleucel in 115 infused patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) from the single-arm, open-label, multicenter, global, phase II JULIET trial (ClinicalTrials.gov identifier: NCT02445248), with a median follow-up of 74.3 months. The median duration of response (DOR) was not reached; the 60-month, relapse-free probability was 61% among responders. Higher relapse-free probability (DOR >70%) was observed in females and those with less than two baseline International Prognostic Index risk factors or with baseline stage I/II disease. The estimated probability of progression-free survival at 60 months was 28%. The probability of overall survival (OS) at 60 months was 32% for all infused patients and 56% for those achieving complete or partial response. Baseline characteristics associated with achieving a response at any time after infusion included relapsed versus refractory disease, one versus two or more bridging regimens, lactate dehydrogenase level ≤upper limit of normal (ULN) versus >ULN, and C-reactive protein levels <15 mg/L versus >15 mg/L. Baseline characteristics associated with long-term OS included lactate dehydrogenase ≤ULN and C-reactive protein <15 mg/L. No new safety signals or secondary T-cell malignancies were reported. These findings continue to support the curative potential of tisagenlecleucel in a subset of patients with r/r LBCL.

> **中文摘要：**
> 我们报告了来自单臂、开放标签、多中心、全球性II期JULIET试验（ClinicalTrials.gov标识符：NCT02445248）中115例接受输注的复发/难治性大B细胞淋巴瘤患者使用替沙仑基奥仑赛的5年分析结果，中位随访时间为74.3个月。中位缓解持续时间尚未达到；在缓解者中，60个月无复发概率为61%。在女性患者、基线国际预后指数风险因素少于两个的患者或基线I/II期疾病患者中观察到更高的无复发概率（缓解持续时间>70%）。60个月时的估计无进展生存概率为28%。所有输注患者的60个月总生存概率为32%，而在达到完全或部分缓解的患者中为56%。与输注后任何时间获得缓解相关的基线特征包括：复发与难治性疾病、一种与两种或更多桥接方案、乳酸脱氢酶水平≤正常值上限与>正常值上限，以及C反应蛋白水平<15 mg/L与>15 mg/L。与长期总生存相关的基线特征包括乳酸脱氢酶≤正常值上限和C反应蛋白<15 mg/L。未报告新的安全性信号或继发性T细胞恶性肿瘤。这些发现持续支持替沙仑基奥仑赛在一部分复发/难治性大B细胞淋巴瘤患者中具有治愈潜力。

### 第二部分 AI 大师评价

本研究旨在通过JULIET试验的5年长期随访数据，评估CAR-T疗法替沙仑基奥仑赛在复发/难治性大B细胞淋巴瘤患者中的持久疗效与安全性。核心发现证实了该疗法在部分患者中具有长期治愈潜力，特别是60个月无复发概率达61%，并明确了女性、低IPI风险、早期分期以及乳酸脱氢酶和C反应蛋白水平正常等与长期获益相关的基线特征。其创新性在于提供了迄今为止最长的CAR-T疗法随访数据之一，为精准筛选优势人群提供了关键依据。局限性主要源于单臂、开放标签的II期试验设计，缺乏随机对照，且样本量有限，可能影响结果的外推性。

---

## 13. 老年癌症患者综合老年评估与管理的成本效用：基于模型的经济学评价。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41118610)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41118610
**DOI：** 10.1200/JCO-25-00248

### 第一部分 原文与翻译

**英文原标题：** Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation.

> **英文摘要：**
> PURPOSE: Geriatric assessment and management (GAM) is a guideline-recommended strategy for optimizing cancer management among older adults. A recent cost-utility analysis of the Canadian 5C randomized controlled trial (RCT) found GAM to be cost effective for selected groups. This study aimed to assess the cost-utility of GAM plus usual care (UC) versus UC alone in older adults with cancer using a decision model and best available evidence from four international RCTs-GAIN, GAP70, INTEGERATE, and 5C.
> 
> METHODS: For the model, we used pooled data from four RCTs and peer-reviewed literature. Deterministic and probabilistic analyses were performed from the Canadian health care payer perspective, applying a 6-month time horizon. Sensitivity analyses included per-trial scenario analyses, 1-year time horizon, and US health care payer perspective. We reported costs per quality-adjusted life year (QALY) and incremental net monetary benefit (INMB).
> 
> RESULTS: The base-case analysis indicated that GAM had an INMB of $599 in Canadian dollars (CAD; 95% credibility interval, -$3,428 to $4,742) with 60.9% probability of being cost effective at a threshold of $50,000 (CAD) per QALY. Trial-specific results varied, with the GAP70 and INTEGERATE trials yielding positive INMB ($2,231 [CAD] and $2,104 [CAD], respectively), suggesting cost-effectiveness, whereas 5C and GAIN resulted in negative INMB (-$489 [CAD] and -$234 [CAD], respectively). Chemotherapy and hospitalization costs were the main driver of costs in both strategies.
> 
> CONCLUSION: GAM is overall cost effective, with results varying across trial scenarios due to differences in chemotherapy dose intensity, hospitalization rates, and associated costs. Future research should prioritize identifying optimal core GAM components, delivery mode, and patient selection criteria to enhance its effectiveness and cost-effectiveness.

> **中文摘要：**
> 目的：综合老年评估与管理（GAM）是优化老年癌症患者管理的指南推荐策略。近期对加拿大5C随机对照试验（RCT）的一项成本效用分析发现，GAM对特定人群具有成本效益。本研究旨在利用决策模型和来自四项国际RCT（GAIN、GAP70、INTEGERATE和5C）的最佳可用证据，评估GAM联合常规治疗（UC）与单独UC在老年癌症患者中的成本效用。
> 
> 方法：对于模型，我们使用了四项RCT的汇总数据和同行评议文献。从加拿大医疗支付方视角出发，采用6个月的时间范围，进行了确定性和概率性分析。敏感性分析包括按试验进行的场景分析、1年时间范围以及美国医疗支付方视角。我们报告了每质量调整生命年（QALY）的成本和增量净货币收益（INMB）。
> 
> 结果：基础案例分析表明，GAM的INMB为599加元（CAD；95%可信区间，-3,428加元至4,742加元），在每QALY 50,000加元（CAD）的阈值下，具有成本效益的概率为60.9%。各试验的具体结果存在差异，GAP70和INTEGERATE试验产生了正的INMB（分别为2,231加元[CAD]和2,104加元[CAD]），提示具有成本效益，而5C和GAIN试验则产生了负的INMB（分别为-489加元[CAD]和-234加元[CAD]）。化疗和住院费用是两种策略成本的主要驱动因素。
> 
> 结论：GAM总体上具有成本效益，但由于化疗剂量强度、住院率及相关成本的差异，结果在不同试验场景中有所变化。未来的研究应优先确定最优的核心GAM组成部分、实施模式和患者选择标准，以提高其有效性和成本效益。

### 第二部分 AI 大师评价

本研究通过整合四项国际RCT数据，构建决策模型，对老年癌症患者综合老年评估与管理（GAM）的成本效用进行了全面的经济学评价。其创新性在于超越了单一试验的局限性，采用模型整合多源证据，并从不同支付方视角和时间范围进行敏感性分析，增强了结果的普适性和稳健性。核心发现表明GAM总体上具有成本效益，但效果在不同试验间存在异质性，主要受化疗强度和住院成本影响。局限性在于模型基于短期（6个月）数据，且未能明确界定GAM的最优实施方案，这为未来研究指明了方向，即需探索标准化的核心要素与精准的患者选择策略。

---

速递结束，祝您工作愉快！